Abstract: An object of the present invention is to provide an antiviral fiber assembly in which an antiviral agent is retained with chemical stability over a long period of time, and which is gentle to the human body. A further object of the present invention is to provide a fiber assembly with cellulose sulfate that can exhibit sufficient antiviral activity over a long period of time. Further, another object of the present invention is to provide a textile product obtained using such a fiber assembly. The present invention provides a fiber assembly with cellulose sulfate, wherein the hyaluronidase inhibitory activity is 50% or higher; and a process for producing a fiber assembly with cellulose sulfate, including treating a fiber assembly with an aqueous cellulose sulfate solution and drying, then treating the same with a pH buffer solution and drying.
Type:
Grant
Filed:
April 30, 2010
Date of Patent:
February 12, 2019
Assignees:
ES FiberVisions CO., LTD., ES FiberVisions Hong Kong Limited, ES FiberVisions LP, ES FiberVisions ApS
Abstract: Disclosed herein is an extract obtainable from Trigonella foenum-graecum. In particular, the extract is obtainable by a process comprising the steps of preparing a mixture of a plant material obtained from Trigonella foenum-graecum and liquid, incubating said mixture for at least 3 hours, heating of said mixture, and recovering a liquid extract from mixture. The extract is useful in the manufacture of various types of compositions, such as pharmaceutical compositions, disinfectant or preservation agents. The pharmaceutical may be used for the treatment or prevention of an inflammatory disease or an infectious condition.
Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.
Abstract: Described herein are compositions and compounds having one or more aziridinyl groups, and methods of making the same. The compounds can also have one or more nitrogen atoms that each can be positively charged. The composition and compounds can inactivate one or more nucleic acid molecules (e.g. a DNA and/or a RNA from a pathogen) in a sample. The sample can comprise a blood or blood product (e.g., donated blood). The compositions and compounds can inactivate any nucleic acid present in a blood or blood product, thereby making the blood or blood product safe for use (e.g., in a transfusion).
Abstract: This document relates to bi-carbonate-buffered dialysis solutions with physiological phosphate content and increased stability. The solutions include an organic ester of phosphoric acid, calcium ions and/or magnesium ions, and optionally additional electrolytes, buffers and glucose in physiologically effective concentrations.
Type:
Grant
Filed:
March 15, 2017
Date of Patent:
January 8, 2019
Assignee:
Fresenius Medical Care Deutschland GmbH
Inventors:
Jochen Huppert, Pascal Mathis, Robert Berlich, Robert Pohlmeier
Abstract: The invention relates to a novel sweet-tasting refreshing beverage, which is free of phosphoric acid and instead contains at least 0.3% by weight/volume of gluconic acid, which is low in minerals, specifically contains less than 250 mg/liter of minerals, which is low in sugar, specifically contains at most 2.5% by weight/volume of sugar, wherein these sugars comprise at least 10% weight/weight galactose and in addition a proportion of isomaltulose and/or tagatose, and which has a glycemic index of at most 35 (GI<35).
Abstract: The present invention provides use of a composition comprising fish oil with low totox value and juice in an oil-in-water emulsion in treatment/resolution of inflammation and/or diseases wherein an underlying cause is inflammation. The invention encompasses further said composition comprising acetylsalicylic acid and/or derivatives and/or analogous thereof. Further the present invention is related to the combined use of a composition of the invention and a therapeutic agent for the treatment of inflammatory diseases or diseases wherein an underlying cause is inflammation.
Abstract: The present invention relates to methods for modifying an agricultural crop comprising treating the agricultural crop with a composition comprising a xyloglucan endotransglycosylase and (a) a polymeric xyloglucan and a functionalized xyloglucan oligomer comprising a chemical group; (b) a polymeric xyloglucan functionalized with a chemical group and a functionalized xyloglucan oligomer comprising a chemical group; (c) a polymeric xyloglucan functionalized with a chemical group and a xyloglucan oligomer; (d) a polymeric xyloglucan, and a xyloglucan oligomer; (e) a polymeric xyloglucan functionalized with a chemical group; (f) a polymeric xyloglucan; (g) a functionalized xyloglucan oligomer comprising a chemical group; or (h) a xyloglucan oligomer, or (a-h) without a xyloglucan endotransglycosylase, in a medium under conditions leading to a modified agricultural crop possessing an improved property compared to the unmodified agricultural crop.
Type:
Grant
Filed:
March 5, 2015
Date of Patent:
November 13, 2018
Assignee:
Novozymes A/S
Inventors:
Alex Berlin, Jason Quinlan, Romil Benyamino
Abstract: The present invention relates, in one aspect, to the use as dermal filler of a cross-linked biopolymer compatible with the tissues of the human organism based on hyaluronic acid cross-linked with urea. The biopolymer of hyaluronic acid and urea may be applied or injected in a soft tissue of human body for tissue augmentation.
Abstract: The growth and/or proliferation of mammalian cells are modulated by modulating the physical interaction between platelets (thrombocytes) and the surface of the cells. Sulfated polysaccharides, preferably glycosaminoglycans, can be used as a medicament for the inhibition of the physical interaction between the cell surface and platelets in the treatment of a medical disorder associated with unwanted cell growth and/or proliferation. The physical interaction between platelets (thrombocytes) and the surface of the cells can be modulated in vitro in order to modulate cell proliferation. Inhibition of the interaction between the cell surface and platelets can inhibit cell growth, and enhancement of the interaction between platelets and the surface of the cell can enhance cell growth.
Abstract: An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G? of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and a method of manufacturing such a composition.
Abstract: Described herein are compositions that include isolated opsonized soluble ?-glucan, methods of making those compositions and methods of using those compositions.
Abstract: A zero-calorie to near-zero-calorie snacking product that, when consumed, provides a feeling of fullness prior to absorption of energy-providing food, i.e., pre-absorptive satiation is disclosed. The snacking product is based on the stimulation of vagal nerve endings in the gastro-intestinal tract by encapsulated capsaicin. The encapsulation of capsaicin avoids the burning sensation in the mouth which may be objectionable to some consumers.
Type:
Grant
Filed:
March 12, 2014
Date of Patent:
October 9, 2018
Assignee:
Altria Client Services LLC
Inventors:
Maria Gogova, Georgios D. Karles, Gerd Kobal, Munmaya K. Mishra
Abstract: A pharmaceutical formulation comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof, up to 5% w/w solids before drying, a component selected from the group consisting of glycerin, lactose, and trehalose and excluding mannitol, and a pharmaceutically acceptable carrier, that preserves stability and bioavailability of the polypeptide is provided.
Abstract: This invention relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. This invention also relates to a medical device including said biomaterial and to a method of repair or treatment including the filling of cavities in the human face or body.
Type:
Grant
Filed:
April 5, 2016
Date of Patent:
October 2, 2018
Assignee:
Cutanea Life Sciences, Inc.
Inventors:
Elisabeth Laugier, Frank Gouchet, Bernard Grandmontagne
Abstract: The present invention relates to a cosmetic composition, in the form of an oil-in-water emulsion, characterized in that it comprises a 2-acrylamido-2-methylpropanesulfonic acid polymer, a copolymer of 2-acrylamido-2-methylpropanesulfonic acid and of an alcohol(meth)acrylate, and a hydrophobic-modified inulin-based amphiphilic polymer, the globules of the said emulsion having a mean size ranging from 15 to 500 microns and the oily phase being present in an amount of less than 35% by weight relative to the total weight of the composition. The invention also relates to a cosmetic process for treating keratin materials.
Abstract: The present invention discloses a mercapto-modified biocompatible macromolecule derivative with a low degree of modification. The mercapto-modified biocompatible macromolecule derivative not only maintains the initial structure, physiological function and biocompatibility as much as possible, but also allows the preparation of the biocompatible macromolecule cross-linked material with a low degree of cross-linking through the effectively chemical cross-linking with the introduced mercapto group. The present invention further discloses a disulfide-bond cross-linked biocompatible macromolecule material with a very low degree of cross-linking.
Abstract: A polygulonic acid sulfate or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof in the preparation of tumor growth and/or metastasis inhibitors are disclosed. The polygulonic acid sulfate or pharmaceutically acceptable salt thereof of the present invention can be used in the preparation of any one or more of tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, C-Met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerizing factor activity inhibitors and actin-aggregation inhibitors.
Type:
Grant
Filed:
July 2, 2014
Date of Patent:
August 28, 2018
Assignee:
SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) containing a functionalizing group including the step of reacting HA with a mixture of: (i) a first cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, and (ii) a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a second cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, to obtain a cross-linked HA containing the functionalizing group. The process provides a cross-linked hyaluronic acid (HA) containing a functionalizing group. The process utilizes a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a cross-linking agent.
Abstract: At equimolar concentrations, D-lactic acid dimer is more cytotoxic than L-lactic acid when directly applied to human HeLa cells in culture. The cytotoxicity of D-lactic acid dimer is an independent effect exclusive of the lower pH when applied to cancer cells in culture. At equimolar concentrations, D-lactic acid dimer is less cytotoxic than L-lactic acid when applied to normal human fibroblasts in culture. D-lactic acid dimer is cytotoxic when applied to human retinoblastoma cells in culture in a dose-dependent fashion. The experimental data supports the cytotoxic mechanism of D-lactic acid dimer via the Warburg effect.
Type:
Grant
Filed:
November 30, 2017
Date of Patent:
July 31, 2018
Inventors:
Joel Steven Goldberg, Joe Brice Weinberg
Abstract: This invention provides a means for screening for lactic acid bacteria having immunoregulatory functions in a simple and rapid manner. This invention provides a method for screening for or producing lactic acid bacteria having immunoregulatory functions comprising determining the number of the test lactic acid bacteria bound to the uromodulin (Umod) protein, lactic acid bacteria obtained by such method, and an immunoregulatory composition comprising such lactic acid bacteria.
Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.
Type:
Grant
Filed:
May 8, 2015
Date of Patent:
July 24, 2018
Assignee:
ASCENDIS PHARMA A/S
Inventors:
Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
Abstract: The present invention relates to a combination comprising a hyaluronic acid or a salt thereof and a sulphated polysaccharide of which the molecular weight is between 5 and 25 kDa, which is of use in particular for combating the signs of skin ageing or for treating and healing skin wounds.
Type:
Grant
Filed:
April 30, 2015
Date of Patent:
June 12, 2018
Assignee:
PIERRE FABRE DERMO-COSMETIQUE
Inventors:
Stéphane Poigny, Hélène Hernandez-Pigeon, Jean-Hilaire Saurat, Gürkan Kaya
Abstract: The present invention relates to a process for an epimerization of a saccharide in a microdevice consisting of a network of micron-sized channels in presence of molybdenum containing catalyst. It further relates to the use of a microdevice consisting of a network of micron-sized channels for the epimerization reaction of saccharides and the oligomerization of the thus obtained epimerized saccharide, preferably into manno-oligosaccharides.
Abstract: The present invention provides anti-thrombogenic compositions, including anti-thrombogenic vascular grafts. In certain embodiments, the compositions comprise decellularized tissue coated with an anti-thrombogenic coating. The present invention also provides methods of preparing anti-thrombogenic compositions and methods of treatment comprising implanting the anti-thrombogenic compositions into a subject in need thereof.
Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-?-L-arabinose (Ara) residues.
Type:
Grant
Filed:
April 4, 2017
Date of Patent:
May 22, 2018
Assignee:
Galectin Therapeutics, Inc.
Inventors:
Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
Abstract: Compositions are disclosed herein comprising poly alpha-1,3-glucan or poly alpha-1,3-1,6-glucan polymer having an open-cell pore structure with an average pore size of about 100 nm to about 3000 nm in diameter. Such polymers have enhanced aqueous liquid absorption capacity, and can be comprised in various products having aqueous liquid absorption function. Methods of preparing glucan polymers of the compositions provided herein are also disclosed.
Abstract: The present invention relates to carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles useful as vaccine adjuvants of formula 1 The present invention also provides process for preparation of carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles. The carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles as vaccine adjuvants are useful in formulations for therapeutic and prophylactic vaccines against bacterial, viral, protozoan infections and cancer.
Type:
Grant
Filed:
January 8, 2016
Date of Patent:
May 15, 2018
Assignee:
Council of Scientific and Industrial Research
Abstract: Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.
Type:
Grant
Filed:
May 9, 2012
Date of Patent:
April 17, 2018
Assignee:
Biothera, Inc.
Inventors:
Nandita Bose, Anissa S. H. Chan, Michael E. Danielson, Mary A. Antonysamy, John P. Vasilakos, Keith B. Gorden, Steven M. Leonardo, William J. Grossman
Abstract: Disclosed herein are inventive stable homogenized biomass hetero-colloids, their production and uses. Such biomass hetero-colloids comprise biomass derived solid particle colloid matter and at least 15% (w/w) biomass derived soluble colloid matter. The novel biomass hetero-colloids provide an inventive approach for the application of biologically active compounds. Bio-actives are made available in an innovative form involving low intervention processing and enhancing the biological availability.
Abstract: Embodiments relate to an ophthalmology microscopy-system and a method of operating an ophthalmology microscopy-system which allow for an at least partial or full removal of liquids and gels used in ophthalmology for application in an eye of a patient in an particularly efficient way. Further embodiments relate to a product such as a liquid or a gel usable for an application in an eye of a patient, wherein the product has a high transmittance and, nevertheless, may be made visible particularly well.
Type:
Grant
Filed:
October 27, 2014
Date of Patent:
March 20, 2018
Assignee:
CARL ZEISS MEDITEC AG
Inventors:
Anja Seiwert, Christoph Hauger, Roland Guckler, Claude Moissonnier
Abstract: The present invention discloses a process for the production of chondroitin sulphate with an average molecular weight (Mw) of 10-30 kDa by chemical sulphation starting from an unsulphated chondroitin backbone, obtained in turn by acid hydrolysis of capsular polysaccharide K4 made directly from E. coli strain O5:K4:H4, or directly produced from a genetically modified strain of E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate, unlike the sulphation obtained with the synthesis methods described to date.
Abstract: A composition includes a Euglena lysate and cellular components and residual media remaining from a fermentation process that produced a Euglena biomass and the Euglena lysate. The cellular components may include one or more beta-glucan polymer chains having a molecular weight of 1.2 to 580 kilodaltons (kDa).
Type:
Grant
Filed:
June 9, 2016
Date of Patent:
February 27, 2018
Assignee:
ALGAEON, INC.
Inventors:
Brad M. Cox, Derek E. Jamrog, Kip R. Zurcher
Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.
Abstract: The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.
Type:
Grant
Filed:
April 22, 2016
Date of Patent:
February 20, 2018
Assignee:
Board of Regents, The University of Texas System
Abstract: When line graphs are displayed on coordinates having a horizontal axis as a time axis and a vertical axis as an axis representing examination values, a line graph is generated in such a manner that data points representing examination data are connected to each other by a line in a case where a time interval between examinations temporally next to each other is less than a maximum line-connection interval for an examination item, and in such a manner that data points representing examination data are not connected to each other in a case where the time interval between examinations temporally next to each other exceeds the maximum line-connection interval for the examination item. Plural line graphs overlapping with each other are displayed on the coordinates.
Abstract: The instant invention relates to a color changing composition in the form of an emulsion comprising, at least: a) microcapsules containing releasable colorant(s), said microcapsules comprising: —a core comprising one organic material, —at least one layered coating surrounding said core, the layered coating comprising at least one polymer, at least one colorant, and advantageously at least one lipid-based material, b) at least partially neutralized, crosslinked acrylic homopolymers or copolymers preferably in a non-particulate form.
Abstract: High levels of bacterial flagella in a sample such as a gastrointestinal sample and/or low levels of anti-flagella antibodies serve as an indication for metabolic syndrome (such as insulin resistance, hypertension, elevated cholesterol, increased risk for blood clotting, and obesity) with highest levels of adiposity. An intervention that reduces the level and/or activity of flagella in the gastrointestinal tract can mitigate the severity of metabolic syndrome or in protecting against the development of metabolic syndrome.
Abstract: A process for producing a water-insoluble shaped material, including a step of treating a raw material shaped material containing a water-soluble salt of a polyanionic polysaccharide with a treatment liquid containing an acid anhydride to insolubilize the raw material shaped material in water, and the process makes it possible to simply produce a water-insoluble shaped material in which intrinsic characteristics of the polyanionic polysaccharide being a raw material are retained, which has a high safety in that a chemical crosslinking agent is not required, and which is useful as a medical material, a food material, a cosmetic material, and the like.
Type:
Grant
Filed:
August 22, 2014
Date of Patent:
January 30, 2018
Assignee:
DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD.
Abstract: The invention provides a method for combating biofilm, said method comprising contacting a biofilm with an alginate oligomer. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use in the treatment or prevention of a biofilm infection in a subject. In another aspect the method can be used to combat biofilms, on abiotic surfaces, e.g. for disinfection and cleaning purposes.
Abstract: When manufacturing a sugar chain compound having an activating group, there was a problem with the ammonium carbonate method that is the conventional technology that during the process of introducing an amino group at the reducing terminal of the sugar chain, the unit sugar located at the reducing terminal of the sugar chain is subjected to ring-opening, thus causing a mixture of ? and ? anomers to be produced.
Abstract: The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.
Type:
Grant
Filed:
April 14, 2016
Date of Patent:
January 2, 2018
Assignee:
Allergan Industrie, SAS
Inventors:
Cecile Gousse, Pierre F. Lebreton, Nicolas Prost
Abstract: The present invention relates to a biological method for assaying peptidoglycans (PGN) in a sample, particularly a sample of glucose polymers. The PGN assay includes: a) treating the glucose polymer sample by sonication, heating, and/or alkalizing; b) placing the treated sample or a dilution thereof in contact with a recombinant cell expressing an exogenous TLR2 (toll-like receptor 2) and a reporter gene directly dependent on the signaling pathway associated with the TLR2. The reporter gene codes for a colored or fluorescent protein or for a protein the activity of which is measurable with or without a substrate; c) measuring the reporter gene signal; and d) determining the amount of PGN in the sample using a standard curve of the correlation between the amount or PGN and the strength of the reporter gene signal.
Type:
Grant
Filed:
March 25, 2014
Date of Patent:
January 2, 2018
Assignee:
Roquette Freres
Inventors:
Pierre Lanos, Marc Biguet, Roselyne Bernard, Fabrice Allain, Mathieu Carpentier, Agnès Denys, Héla Hacine-Gherbi
Abstract: Various embodiments disclosed relate to treatment fluids comprising a compound of the formula (I): wherein G1, G2, L1, L2, L3, q, and r are defined herein. Various other embodiments relates to methods of treating subterranean formations with such treatment fluids.
Type:
Grant
Filed:
December 20, 2013
Date of Patent:
November 28, 2017
Assignee:
Halliburton Energy Services, Inc.
Inventors:
Jimmie Dean Weaver, Jr., James William Ogle
Abstract: The use of a polysaccharide in a method for improving the flora of the colon of nursing infants and/or infants, thus treating or preventing colic and enterocolitis and therefore improving and/or generally stimulating the intestinal well-being of nursing infants and/or infants. A food composition for feeding nursing infants and/or infants, including at least one polysaccharide for treating or preventing colic and enterocolitis and improving and/or stimulating the intestinal well-being of nursing infants and/or infants. The polysaccharide used is a branched maltodextrin, preferably with a molecular mass of between 400 and 4500.
Type:
Grant
Filed:
November 13, 2013
Date of Patent:
November 28, 2017
Assignee:
Roquette Freres
Inventors:
Laetitia Guerin-Deremaux, Virginie Teichman-Dubois, Daniel Wils
Abstract: Immunostimulatory compositions and methods of use are described to either enhance or diminish the immune stimulation effects of a honey or honey isolate by recognition of the presence of type II arabinogalactan compounds and utilising this knowledge to tailor the concentration of such compounds thereby adjusting the immune stimulation effects.
Type:
Grant
Filed:
July 22, 2016
Date of Patent:
November 28, 2017
Assignee:
Comvita New Zealand Limited
Inventors:
Ian Sims, Jonathan McDonald Counsell Stephens, Ralf Christian Schlothauer, Swapna Gannabathula
Abstract: The present invention provides a method to prepare polysaccharides from Hirsutella sinensis. The prepared polysaccharides can reduce hyperglycemia and insulin resistance, and can therefore be used to prevent and treat type 2 diabetes and related conditions.
Type:
Grant
Filed:
September 15, 2015
Date of Patent:
November 28, 2017
Assignee:
Chang Gung Biotechnology Corp.
Inventors:
Yun-Fei Ko, Jan Martel, Jian-Ching Liau, I-Te Chang, Chien-Sheng Lee, Wei-Chang Wang, Chen-Yaw Chiu, Chih-Jung Chang, Chuan-Sheng Lin, Tsung-Ru Wu, Chia-Chen Lu, David Marcelo Ojcius, Hsin-Chih Lai, Ding-E Young
Abstract: The present invention relates to stable polymer matrix compositions comprising high concentrations (from about 1.5% w/w to about 3.5% w/w) sodium hyaluronate obtained from a Streptococcus zooepidemicus source and a non-ionic polymer. The polymer matrix composition further comprises polyethylene glycol and methylparaben, and utilizes ingredients that are of pharmaceutical or compendial grade. The polymer matrix compositions may optionally comprise an active ingredient. The present polymer matrix compositions may be used in the treatment of wounds, burns, certain dermatological conditions, vaginal dryness, and in topical, transdermal delivery and sustained release of active ingredients.